Published in J Biol Chem on May 11, 2001
Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37
Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med (2002) 3.16
Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity. J Exp Med (2006) 1.80
The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J Biol Chem (2004) 1.69
VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci (2006) 1.65
The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol (2004) 1.61
Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol (2005) 1.59
MicroRNA-10 regulates the angiogenic behavior of zebrafish and human endothelial cells by promoting vascular endothelial growth factor signaling. Circ Res (2012) 1.56
Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway. Cardiovasc Res (2009) 1.53
NHERF-2 maintains endothelial homeostasis. Blood (2012) 1.47
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest (2006) 1.36
Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab (2004) 1.29
Focal adhesion kinase controls cellular levels of p27/Kip1 and p21/Cip1 through Skp2-dependent and -independent mechanisms. Mol Cell Biol (2006) 1.20
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res (2011) 1.18
Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res (2006) 1.14
The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. Am J Pathol (2004) 1.12
Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol (2009) 1.08
A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. J Biol Chem (2005) 1.07
Distinct role of PLCbeta3 in VEGF-mediated directional migration and vascular sprouting. J Cell Sci (2009) 1.07
A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters. Mol Cell Biol (2004) 1.01
Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation. Front Immunol (2012) 0.97
DNA conjugated SWCNTs enter endothelial cells via Rac1 mediated macropinocytosis. Nano Lett (2012) 0.95
Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res (2008) 0.95
The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood (2013) 0.93
Regulation of endothelial glutathione by ICAM-1 governs VEGF-A-mediated eNOS activity and angiogenesis. Free Radic Biol Med (2006) 0.93
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther (2011) 0.92
VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2-dependent Ca2+ signaling. Proc Natl Acad Sci U S A (2014) 0.91
Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol (2012) 0.91
The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep (2013) 0.90
Differential effects of cyclic and static stretch on coronary microvascular endothelial cell receptors and vasculogenic/angiogenic responses. Am J Physiol Heart Circ Physiol (2008) 0.89
Embryonic vasculogenesis and hematopoietic specification. Organogenesis (2008) 0.89
Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets. Pharmacol Ther (2012) 0.88
Fast rearrangement of the neuronal growth cone's actin cytoskeleton following VEGF stimulation. Histochem Cell Biol (2012) 0.85
Orphan nuclear receptor TR3/Nur77 improves wound healing by upregulating the expression of integrin β4. FASEB J (2014) 0.84
Role of AKT-glycogen synthase kinase axis in monocyte activation in human beings with and without type 2 diabetes. J Cell Mol Med (2009) 0.83
Single-molecule detection of H₂O₂ mediating angiogenic redox signaling on fluorescent single-walled carbon nanotube array. ACS Nano (2011) 0.82
Differential regulation of orphan nuclear receptor TR3 transcript variants by novel vascular growth factor signaling pathways. FASEB J (2014) 0.81
Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer (2011) 0.80
Fine-tuning the angiogenic response to vascular endothelial growth factor. Circ Res (2008) 0.80
The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep (2015) 0.79
Transcription enhancer factor 3 (TEF3) mediates the expression of Down syndrome candidate region 1 isoform 1 (DSCR1-1L) in endothelial cells. J Biol Chem (2008) 0.79
2,3,7,8-Tetrachlorodibenzo-p-dioxin differentially suppresses angiogenic responses in human placental vein and artery endothelial cells. Toxicology (2015) 0.78
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. Int J Mol Sci (2015) 0.77
Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.76
Expression of circulating vascular endothelial growth factor-antagonizing cytokines and vascular stabilizing factors prior to and following bypass surgery in patients with moyamoya disease. Exp Ther Med (2014) 0.76
Selective assembly of DNA-conjugated single-walled carbon nanotubes from the vascular secretome. ACS Nano (2014) 0.76
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer. Int J Oncol (2015) 0.76
Therapeutic advances in women's cancers. Front Biosci (Schol Ed) (2011) 0.76
The merits of vascular targeting for gynecologic malignancies. Curr Oncol Rep (2005) 0.75
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell (1992) 4.90
Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med (1992) 4.39
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 4.12
Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev (1993) 3.96
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol (1994) 3.76
Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature (1981) 3.71
Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol (1989) 3.44
Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res (1990) 3.35
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med (1994) 3.09
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res (1993) 2.98
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol (1995) 2.96
Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest (2000) 2.92
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol (1993) 2.85
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
Cutaneous basophil hypersensitivity. II. A light and electron microscopic description. J Exp Med (1970) 2.61
Neutrophils emigrate from venules by a transendothelial cell pathway in response to FMLP. J Exp Med (1998) 2.61
Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res (1999) 2.55
Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med (1994) 2.54
Cytochemical localization of certain phosphatases in Escherichia coli. J Bacteriol (1970) 2.43
Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta (1989) 2.40
Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol (2001) 2.38
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res (1996) 2.36
Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med (1996) 2.26
Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol (1991) 2.26
Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res (1995) 2.24
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS (1997) 2.24
Cutaneous basophil hypersensitivity. I. A new look at the Jones-Mote reaction, general characteristics. J Exp Med (1970) 2.21
The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol (1996) 2.15
Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol (1979) 2.15
Regulation of extravascular coagulation by microvascular permeability. Science (1985) 2.11
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol (1982) 2.10
Osteopontin expression and distribution in human carcinomas. Am J Pathol (1994) 2.09
Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell (1992) 2.00
Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer (2009) 2.00
Purification and properties of two acid phosphatase fractions isolated from osmotic shock fluid of Escherichia coli. Biochemistry (1967) 1.96
Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. Prog Allergy (1984) 1.94
Mast cell clones: a model for the analysis of cellular maturation. J Cell Biol (1982) 1.91
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. J Immunol (1971) 1.84
Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res (2001) 1.83
Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res (1995) 1.79
Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst (1979) 1.79
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med (2001) 1.77
Basophilic leukocytes in allergic contact dermatitis. J Exp Med (1972) 1.75
Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med (1979) 1.74
Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res (1993) 1.71
Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol (2000) 1.68
Fibroblast migration in fibrin gel matrices. Am J Pathol (1993) 1.64
Tumor shedding and coagulation. Science (1981) 1.64
Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation (2001) 1.64
Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest (1992) 1.57
Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost (1997) 1.56
Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol (1997) 1.56
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst (1995) 1.55
Cell surface glypicans are low-affinity endostatin receptors. Mol Cell (2001) 1.51
Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest (1996) 1.50
Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Ophthalmol (1996) 1.48
Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol (1995) 1.47
Ultrastructural identification of the mouse basophil. Blood (1982) 1.47
Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am J Pathol (1993) 1.46
Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol (1988) 1.44
Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol (1995) 1.43
Fibronectin in delayed-type hypersensitivity skin reactions: associations with vessel permeability and endothelial cell activation. J Immunol (1981) 1.42
Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem (2000) 1.41
Loss of cell surface material from peritoneal exudate cells associated with lymphocyte-mediated inhibition of macrophage migration from capillary tubes. Lab Invest (1972) 1.41
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer (1997) 1.40
Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int (1992) 1.40
Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol (1995) 1.39
Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys (1993) 1.39
Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation (1999) 1.38
Cellular and vascular manifestations of cell-mediated immunity. Hum Pathol (1986) 1.37
Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood (2000) 1.36
Cutaneous basophilic hypersensitivity: a new interpretation of the Jones-Mote reaction. J Immunol (1969) 1.36
Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. J Invest Dermatol (1982) 1.35
Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev (1983) 1.34
Cloning of DLM-1, a novel gene that is up-regulated in activated macrophages, using RNA differential display. Gene (1999) 1.34
Fibrinogen/fibrin on the surface of macrophages: detection, distribution, binding requirements, and possible role in macrophage adherence phenomena. J Exp Med (1975) 1.33
Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol (1983) 1.33
Antigen-induced IgE-mediated degranulation of human basophils. Lab Invest (1980) 1.32
Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor. J Biol Chem (2001) 1.32
Metallo-enzymes released from Escherichia coli by osmotic shock. II. Evidence that 5'-nucleotidase and cyclic phosphodiesterase are zinc metallo-enzymes. J Biol Chem (1968) 1.32
Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol (1995) 1.30
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res (1983) 1.29
Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating Matrigel-collagen gels. J Histochem Cytochem (1999) 1.27
Role of the basophilic leukocyte in allograft rejection. J Immunol (1971) 1.26
Chemotaxis of basophils by lymphocyte-dependent and lymphocyte-independent mechanisms. J Immunol (1975) 1.26
Biochemical and cytochemical evidence for the polar concentration of periplasmic enzymes in a "minicell" strain of Escherichia coli. J Bacteriol (1970) 1.25
Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol (1996) 1.23
Fibrinogen influx and accumulation of cross-linked fibrin in mouse carcinomas. Cancer Res (1988) 1.23
Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest (1979) 1.22
Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity. J Exp Med (1971) 1.21